All In Biotech

Drug Trial Radar · NCT06973629

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Nov 1, 2028

Study completion May 1, 2029

Sponsor

Lead sponsor
Brainstorm-Cell TherapeuticsIndustry
Sponsor type
Industry
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this two-part clinical trial is: 1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS; followed by 2) further evaluation by providing NurOwn to all participants in an open label extension period. Researchers will compare NurOwn to a placebo (a look-alike substance that contains no drug) to evaluate the efficacy of NurOwn compared to placebo in the treatment of participants with ALS. Participants will: Receive NurOwn or a placebo every 8 weeks for 24 weeks. After that, every participant will receive NurOwn every 8 weeks for an additional 24 weeks. They will visit the clinic approximately every 8 weeks for checkups and tests.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)
  • Amyotrophic Lateral Sclerosis

Interventions

  • Debamestrocel - MSC-NTF (NurOwn)Biological

    MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).

  • PlaceboBiological

    Dulbecco Modified Eagle Medium (DMEM).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the ALSFRS-R total score from baseline to Week 24Time frame: From baseline to Week 24
  2. Frequency and severity of adverse events including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), death, abnormalities in laboratory evaluations, physical examinations, vital signs and electrocardiogram (ECG) assessmentsTime frame: From baseline to Week 48

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California San Diego Medical Center

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado Anschutz Medical Campus School of Medicine

    Aurora, Colorado

  • Nova Southeastern University

    Davie, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • University of South Florida

    Tampa, Florida

  • Northwestern Medicine

    Chicago, Illinois

  • Sean M. Healey & AMG Center For ALS At Massachusetts General Hospital

    Boston, Massachusetts

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Providence ALS Center

    Portland, Oregon

  • Temple University Of The Commonwealth System of Higher Education

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.